United States Health

Bluejay Diagnostics (NASDAQ:BJDX) released baseline data for its SYMON-II clinical validation study featuring 777 evaluable sepsis patients.

Telix Pharmaceuticals (NASDAQ:TLX) commenced U.S. distribution of its brain cancer imaging drug Pixclara with its first patient doses.

Viking Therapeutics (NASDAQ:VKTX) initiated an exploratory trial evaluating oral and dosing maintenance options for its lead obesity candidate, VK2735.

Kamada (NASDAQ:KMDA) expanded its commercial biosimilar portfolio in Israel with the market launch of Ustekinumab-Kamada and Enoxaparin-Kamada.

BD (NYSE:BDX) partnered with the U.S. government to expand domestic manufacturing and supply chain infrastructure for critical medical consumables.

Crescent Biopharma (NASDAQ:CBIO) received FDA clearance for its Investigational New Drug application for CR-002, an antibody-drug conjugate being developed for advanced solid tumors.

Alterity Therapeutics (NASDAQ:ATHE) reported additional Phase 2 analyses showing ATH434 50 mg slowed functional decline in multiple system atrophy by approximately 52% compared with placebo at Week 52.

Abbott (NYSE:ABT) received regulatory clearance from the U.S. Food and Drug Administration for major software capabilities connected to its implanted heart-monitoring platform.

Establishment Labs Holdings (NASDAQ:ESTA) secured U.S. Food and Drug Administration approval for an expanded range of Motiva SmoothSilk Round and Ergonomix breast implants.

GE HealthCare (NASDAQ:GEHC) executed a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for a cash purchase price of $945 million.

Alector (NASDAQ:ALEC) executed an exclusive global licensing agreement with Genentech for AL050, an investigational enzyme replacement therapy targeting Parkinson’s disease.

Harrow (NASDAQ:HROW) closed the acquisition of TYRVAYA from Viatris to expand its commercial ophthalmic portfolio with an approved dry eye treatment.